Tesamorelin 20mg Research Peptide
Tesamorelin is a synthetic GHRH analogue with FDA approval (Egrifta, 2010) for visceral fat reduction in HIV-associated lipodystrophy. This 20mg vial provides a larger research quantity of tesamorelin at ≥99% purity, HPLC and MS/MS verified per batch — suitable for multi-model or extended protocol research applications.
Research Background
Unlike most GHRH analogues, tesamorelin stimulates endogenous GH secretion through pulsatile physiological patterns rather than continuous elevation, which researchers have proposed may preserve GH axis feedback regulation. Beyond its approved lipodystrophy indication, ongoing research includes its effects on hepatic fat in non-HIV NAFLD models, cognitive function in aging populations, and body composition in metabolic syndrome contexts.
Compound Specifications
- Format: Lyophilized powder
- Purity: ≥99% (HPLC verified)
- Quantity: 20mg per vial
- Storage: −20°C, protected from light
- Molecular Weight: 5135.9 Da
Key Research Findings
Phase 3 trials supporting FDA approval demonstrated ~15–18% reduction in visceral adipose tissue over 26 weeks. A 2021 RCT demonstrated tesamorelin significantly improved verbal memory and executive function in older adults with mild cognitive impairment compared to placebo, adding a neurocognitive dimension to its research profile.
Certificate of Analysis
Third-party tested by independent ISO-certified laboratories. HPLC and MS/MS validation performed per batch. COA available on request.
For research and laboratory use only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.
